RAB27B: A Drug Target for Various Diseases (G5874)

Target Name: RAB27B

NCBI ID: G5874

RAB27B

RAB27B: A Drug Target for Various Diseases

RAB27B (RAB27B-GFP) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the RAB27 family of G protein-coupled receptors (GPCRs), which are a superfamily of transmembrane proteins that play a critical role in various physiological processes in the body. RAB27B is known for its role in cell signaling and is involved in the regulation of a wide range of cellular processes, including cell adhesion, migration, and survival.

Drug Targeting

RAB27B is a drug target of great interest due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of a number of potential therapeutic approaches.

In cancer, RAB27B has been shown to promote the growth and survival of various types of cancer cells, including breast, lung, and ovarian cancer. This is because RAB27B plays a role in the regulation of cell signaling pathways that are commonly associated with cancer growth, such as the PI3K/Akt signaling pathway.

In neurodegenerative diseases, RAB27B has been implicated in the development and progression of a wide range of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This is because RAB27B is involved in the regulation of cellular processes that are important for the maintenance of normal brain function, such as the regulation of neurotransmitter release and the maintenance of the integrity of the blood-brain barrier.

In autoimmune disorders, RAB27B has been shown to contribute to the development and progression of a wide range of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. This is because RAB27B plays a role in the regulation of immune cell function and has been implicated in the development of autoimmune diseases.

Bioavailability and Administration

RAB27B is expressed in various tissues of the body and can be isolated from cells or cell culture supernatants using techniques such as affinity chromatography. It can then be used for various applications, including as a drug target, for research, or for diagnostic purposes.

For the purpose of drug targeting, RAB27B can be expressed in various cell types and used for various treatments, such as small molecule inhibitors or antibodies. These treatments can be administered to the patient, either alone or in combination with other therapies, to either prevent or treat the development or progression of various diseases.

Conclusion

RAB27B is a protein that is involved in a wide range of cellular processes in the body and has been implicated in the development and progression of various diseases. Its potential as a drug target makes it an attractive target for research and clinical development. Further studies are needed to fully understand the role of RAB27B in various diseases and to develop effective treatments.

Protein Name: RAB27B, Member RAS Oncogene Family

Functions: Small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate homeostasis of late endocytic pathway, including endosomal positioning, maturation and secretion (PubMed:30771381). Plays a role in NTRK2/TRKB axonal anterograde transport by facilitating the association of NTRK2/TRKB with KLC1 (PubMed:21775604). May be involved in targeting uroplakins to urothelial apical membranes (By similarity)

The "RAB27B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB27B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets